Update on EMA’s Brexit preparedness

October 9, 2018 – The European Medicines Agency’s (EMA) Brexit preparedness business continuity plan (BCP) entered into its third phase on 1 October 2018, as announced at the beginning of August 2018. The temporary suspension or reduction of additional activities in this phase allows the Agency to safeguard core activities related to the evaluation and supervision of medicines while the Agency prepares for the consequences of the United Kingdom’s (UK) exit … (leggi tutto)